Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Ionis Pharmaceuticals is a leading antisense oligonucleotide (ASO) drug discovery platform company with 50+ drugs in development across cardiovascular, neurological, and rare diseases. The company generates revenue through licensing partnerships (notably with AstraZeneca, Biogen, Roche) and royalties on commercialized drugs like Spinraza (SMA treatment) and Tegsedi, while maintaining a deep pipeline with multiple Phase 3 assets targeting high-value indications. Stock performance is driven by clinical trial readouts, regulatory approvals, and partnership deal announcements rather than near-term profitability.
Ionis operates a capital-efficient drug discovery model by developing ASO candidates through early-stage clinical trials (Phase 1/2), then licensing them to large pharma partners who fund late-stage development and commercialization in exchange for upfront payments ($100M-$500M+), milestone payments (potentially $1B+ per program), and tiered royalties (typically 10-20% of net sales). This asset-light approach allows the company to maintain a broad pipeline (50+ programs) without bearing full commercialization costs. The proprietary ASO chemistry platform provides competitive moats through extensive patent protection and manufacturing expertise at the Carlsbad facility.
Phase 2/3 clinical trial data readouts for lead programs (eplontersen cardiovascular outcomes, olezarsen triglyceride reduction, donidalorsen attack rate reduction)
New partnership announcements with upfront payments and deal structures (recent deals average $150M-$400M upfront)
FDA/EMA regulatory decisions and approval timelines for late-stage assets
Spinraza royalty trends and competitive dynamics in SMA market (facing competition from Evrysdi and gene therapy)
Pipeline expansion announcements and Investigational New Drug (IND) filings for novel targets
Clinical trial failure risk - ASO platform has ~10-15% Phase 3 success rate industry-wide; single trial failure can eliminate $500M+ in expected milestone/royalty value
Regulatory approval uncertainty - FDA/EMA standards for rare disease and cardiovascular endpoints evolving; potential for Complete Response Letters delaying commercialization by 1-2 years
Competitive technology platforms - mRNA therapeutics (Moderna, BioNTech), siRNA (Alnylam), and gene editing (CRISPR) targeting similar indications with potentially superior efficacy or dosing profiles
Spinraza erosion - Roche's Evrysdi and Novartis gene therapy Zolgensma capturing SMA market share; royalty revenue at risk of 20-30% decline through 2028
Partnership concentration - Top 3 partners (AstraZeneca, Biogen, Roche) represent 70%+ of pipeline value; loss of key relationship or partner deprioritization significantly impacts development trajectory
Manufacturing scale-up challenges - ASO production requires specialized chemistry; capacity constraints at Carlsbad facility could limit ability to supply multiple commercial products simultaneously
Cash burn sustainability - $500M annual negative FCF with $1.5B cash position implies 3-year runway without additional financing; may require dilutive equity raise or asset sales if pipeline milestones delayed
Convertible debt maturity - $575M convertible notes due 2026-2027 require refinancing or conversion; if stock price below conversion price, forced debt repayment strains liquidity
Negative ROE/ROA - 44% negative ROE reflects accumulated losses; pathway to profitability requires 3+ commercial products generating combined $300M+ annual royalties
low - Biotech drug development timelines and regulatory processes are largely insulated from GDP fluctuations. Patient demand for approved rare disease and cardiovascular therapies is non-discretionary. However, partnership activity and M&A valuations can be affected during severe recessions as large pharma partners reduce business development spending.
Rising interest rates negatively impact valuation through higher discount rates applied to long-dated cash flows (most pipeline value is 3-10 years out). The company's $1.9B debt load (2.41 debt/equity ratio) includes convertible notes with fixed rates, limiting direct financing cost impact, but refinancing risk exists. Higher rates also reduce biotech sector risk appetite, compressing multiples for pre-profitable companies. The 2.79 current ratio provides adequate liquidity buffer against rate-driven credit tightening.
Moderate exposure - While operations are not credit-dependent, the company relies on capital markets access for funding given negative FCF. Tighter credit conditions reduce ability to raise capital through debt or equity offerings, potentially forcing dilutive financings or partnership deals on less favorable terms. Investment-grade pharma partners' willingness to commit large upfront payments can also decline during credit stress.
growth - Attracts biotech specialists and growth investors focused on pipeline optionality rather than current earnings. The 156% one-year return and 89% six-month return reflect momentum-driven trading around clinical catalysts. High R&D spending (negative 67% operating margin) and pre-profitability status appeal to investors willing to underwrite 5-10 year development timelines for potential blockbuster approvals. Not suitable for value or income investors given negative cash flow and no dividend.
high - Biotech stocks typically exhibit 40-60% annualized volatility driven by binary clinical trial outcomes. Single trial readout can move stock 20-40% in either direction. The 156% one-year return demonstrates momentum volatility. Estimated beta of 1.3-1.5 to biotech sector indices, with idiosyncratic risk from concentrated pipeline events. Options market typically prices 50-70% implied volatility around key data readouts.
